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Abstract
Background
Chronic Obstructive Pulmonary Disease (COPD) impacts differently on patients at similar
grades, suggesting that factors other than lung function may influence patients’ experience
of the disease. Recent studies have found associations between genetic variations and
patient-reported outcomes (PROs). Identifying these associations might be fundamental to
predict the disease progression and develop tailored interventions. This systematic review
aimed to identify the genetic variations associated with PROs in COPD.
Methods and findings
Databases were searched until July 2017 (PROSPERO: CRD42016041639) and additional
searches were conducted scanning the reference list of the articles. Two independent
reviewers assessed the quality of studies using the Q-Genie checklist. This instrument is
composed of 11 questions, each subdivided in 7 options from 1 poor-7 excellent. Thirteen
studies reporting 5 PROs in association with genes were reviewed. Studies were rated
between “good quality” (n = 8) and “moderate” (n = 5). The most reported PRO was fre-
quency of exacerbations (n = 7/13), which was mainly associated with MBL2 gene variants.
Other PRO’s were health-related quality of life (HRQOL) (n = 4/13), depressive symptoms
(n = 1/13), exacerbation severity (n = 1/13) and breathlessness, cough and sputum (n = 1/
13), which were commonly associated with other genetic variants.
Conclusions
Although a limited number of PRO’s have been related to genetic variations, findings sug-
gest that there is a significant association between specific gene variants and the number/
severity of exacerbations, depressive symptoms and HRQOL. Further research is needed
to confirm these findings and assess the genetic influence on other dimensions of patients’
lives, since it may enhance our understanding and management of COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a multifactorial, heterogeneous and pro-
gressive condition that affects 210 million people worldwide[1]. Severity of COPD is usually
classified according to the degree of airway obstruction (assessed with spirometry), neverthe-
less it has been acknowledged that people at similar grades of COPD report different disease
impacts[1]. These different reports among patients suggest that factors beyond lung function
influence patients’ experience of the disease. Indeed, upstream factors, such as the presence of
specific genetic variants, have already been reported to play a role in this matter[2]. For exam-
ple, polymorphisms in SERPINA1 usually lead to a deficiency of the α1 antitrypsin, affecting
1–2% of all COPD cases[3]. Additionally, the role of other candidate genes in the pathogenesis,
comorbidities and outcomes of the disease have been studied[4].
Patient-reported outcomes (PROs) are a set of health outcomes directly reported by
patients and may include symptoms (dyspnea, cough, pain, fatigue), exacerbation frequency
and health status, among others [5]. These outcomes are accepted as the most faithful repre-
sentation of patients’ perspectives of the impact of the disease and treatment benefits[6]. The
needed of assessing PROs has been considerably highlighted in the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) 2017 update, which suggests that COPD classifica-
tion should now be based on exacerbation frequency and patient’s perception of their symp-
toms rather than on lung function only [1].
In the last years, it has become more evident that there is a strong association between
PROs and genetics, namely in lung cancer[7], which may suggest that strong associations may
also exist between genetics and PROs in COPD. However, a review of the known associations
has never been conducted. The combination of genetics and PROs would be valuable to iden-
tify patients susceptible to PROs deficits, understand the diagnosis, predict disease progression
and develop tailored and timely interventions [8].
Therefore, the focus of this systematic review was to synthetize the genetic variations associ-
ated with different PROs in COPD.
Methods
Search strategy
The systematic review protocol was registered at Prospective Register of Systematic Reviews
(PROSPERO) (ref CRD42016041639). A comprehensive systematic search was conducted in
May 2016 and weekly updates were performed until July 2017 in the following medical data-
bases: PubMed (1950–2016), Scopus (1960–2016) and Web of Science (1900–2016). The
PICOS (Populations, Intervention, Comparison, Outcome and Study Design) framework was
used to develop literature search strategies, however Intervention (I) and Comparison (C)
terms were omitted as they were not applicable to the present review [9]. Accordingly, the
search terms were based on a combination of the following keywords: [(COPD OR "chronic
obstructive pulmonary disease" OR emphysema OR "chronic bronchitis") AND ("genetic asso-
ciations" OR "genetic profile" OR "genetic analysis" OR gene) AND (dyspnea OR dyspnoea OR
breathlessness OR fatigue OR cough OR depression OR anxiety OR "daily living" OR "quality
of life" OR mood OR "well-being" OR “frequency of exacerbation” OR exacerbations OR "hos-
pital admissions" OR "hospital length of stay" OR "acute exacerbations" OR “physical activity”
OR "physical fitness" OR “physical function” OR “sputum production” OR phlegm OR pain
OR “patient-reported outcomes” OR “patient-centered outcomes” OR “patient-centered out-
comes”)]. The full search strategy can be found in supplementary material (S1 Table). The ref-
erence lists of the selected articles were also scanned for other potential eligible studies.
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Eligibility criteria
Studies were considered eligible if included adult patients (>18 years old) diagnosed with
COPD and associated a genetic profile to one or more PRO. For the purpose of this systematic
review, PRO were defined, according to the Cochrane Collaboration definition, as “reports
coming directly from patients about how they feel or function in relation to a health condition
and its therapy without interpretation by healthcare professionals or anyone else” [10]. Studies
were excluded if they were conducted in animals, were written in languages other than English,
Spanish, French or Portuguese and did not differentiate chronic obstructive diseases (i.e., pre-
sented pooled data from several chronic obstructive diseases such as asthma, COPD and bron-
chiectasis). Book chapters, review papers, abstracts of communications on meetings, letters to
the editor, commentaries to articles, unpublished work and study protocols were not consid-
ered suitable and, therefore, were also excluded from this study. This systematic review was
reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analy-
sis (PRISMA) (S2 Table) [9, 11].
Quality assessment
Quality, internal validity and risk of bias of the included studies were assessed using the Qual-
ity of genetic association studies checklist (Q-Genie) [12]. This instrument is composed of 11
questions to assess “rationale for study”, “selection and definition of outcome of interest”,
“selection and comparability of comparison groups”, “technical classification of the exposure”,
“non-technical classification of the exposure”, “other source of bias”, “sample size and power”,
“a priori planning of analysis”, “statistical methods and control for confounding”, “testing of
assumptions and inferences for genetic analysis” and “appropriateness of inferences drawn
from results”. The Q-Genie checklist has 7 possible answers for each question (i.e., “1 (poor)”,
“2”, “3 (good)”, “4”, “5 (very good)”, “6”, “7 (excellent)”). The overall quality of studies is classi-
fied as “poor quality” if score is35, “moderate quality” if score is>35 and45, and “good
quality” (>45), for studies having control groups. For studies without control groups, values
for the parameters listed above are32,>32 and40, and>40, respectively[12]. Two review-
ers assessed the quality of studies independently. Disagreements were solved consulting a third
reviewer.
Studies selection and data extraction
First, duplicates were removed and one reviewer performed the initial screening of title,
abstract and keywords of studies based on the type of publication and relevance for the scope
of the review. Then the full-text of each potentially relevant study was screened for content to
decide its inclusion in the review. For each accepted study, one reviewer extracted the follow-
ing data to a previously structured table: last author’s name and year of publication, study
design, sample characteristics (i.e., sample size, age, gender and COPD severity), PRO evalu-
ated and outcome measures used, gene associated with the identified PRO and type of associa-
tion between the PRO and the identified gene. Two independent reviewers further checked
the extracted data for accuracy and completeness. Reviewers resolved disagreements by
consensus.
Data analysis
Consistency of the studies quality assessment (performed by the two reviewers), was explored
with the Cohen’s kappa. The value of Cohen’s kappa vary from 0 to 1 and can be interpreted
as: i) 0.00–0.20: slight agreement; ii) 0.21–0.40: fair agreement; iii) 0.41–0.60: moderate
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agreement; iv) 0.61–0.80: substantial agreement; v) 0.81–1.00: almost perfect agreement[13].
Statistical analysis was performed using IBM SPSS Statistics version 24.0 (IBM Corporation,
Armonk, NY, USA).
Results
Search strategy
Database search identified 1889 studies of potential interest. After duplicates removal, 1259
articles were analyzed for relevant content. From these, 1206 were excluded due to the follow-
ing reasons: non-original articles (n = 575), absence of PRO/genetic associations (n = 387),
non-specific for COPD (n = 122), studies conducted in animals (n = 98), studies written in
other languages rather than English, Spanish, French or Portuguese (n = 24). The full-text of
the remaining 53 potentially relevant articles was assessed and 40 articles were excluded. Rea-
sons for exclusion included: absence of PRO (n = 19), absence of genetic association (n = 19),
not specific for COPD (n = 1) and unavailability of the article even after contacting the authors
(n = 1). In total, 13 articles were included, all published in English. A detailed diagram of the
review process is presented in Fig 1.
Quality assessment
Articles scored between 39 and 55 in the Q-Genie checklist [12] (Table 1). Six articles were
classified as studies without control group [14–19], from which five presented “good quality”
and one was of “moderate quality”. The remaining articles, were classified as “studies with con-
trol group”, from which four were “moderate quality” and the remaining three of “good qual-
ity”. Items with the lowest classification were the “selection and comparability of comparison
groups” and “sample size and power”. The agreement between the two independent reviewers
was almost perfect (k = 0.83; 95% CI 0.29–1; p = 0.002).
Study characteristics
Study characteristics are presented in Table 2. A total of 6520 patients with COPD with a mean
age range of 63.2–71.8 years old, mainly males (4638 males– 71,13%) participated in the 13
studies included. Studies designs were observational (n = 9) [14, 15, 19–25] and pre and post
intervention (n = 4)[16–18, 26].
The most frequent genetic variants were the mannose-binding lectine (MBL2) gene
variants (n = 3) [14, 20, 22] and the beta-2 adrenoceptor gene (ADRB2) polymorphisms
(n = 2) [16, 17]. Other genetic variants observed were group component (GC) single
nucleotide polymorphisms (SNPs) (n = 1) [25], HHIP/CHRNA/FAM13A variants (n = 1)
[15], SERPINA 11478 G>A variant (n = 1) [23], 25-hydroxyvitamin D receptor (VDR)
polymorphisms (n = 1) [24], C-C motif chemokine ligand 1 (CCL1) SNPs (n = 1) [19], sero-
tonin transporter gene variant (SLC6A4) (n = 1) [21], heme-oxygenase (HO-1) gene promo-
tor polymorphism (n = 1) [18] and epoxide hydrolase 1 (EPHX1) polymorphisms (n = 1)
[26].
The PRO most assessed was the exacerbation frequency (n = 7) [14, 15, 20, 22–25], followed
by health-related quality of life (n = 4) [16–18, 26], anxiety and depression (n = 1) [21], exacer-
bation severity [19] and breathlessness, cough and sputum (n = 1)[16]. Exacerbation frequency
was assessed using daily diaries (n = 3)[23–25], phone calls (n = 3)[14, 15, 20], questionnaires
(n = 1)[15] and patient interviews (n = 1)[22]. Anxiety and depression were assessed using the
Hospital Anxiety and Depression Scale (HADS)(n = 1)[21], and health-related quality of life
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and respiratory health status using the St George Respiratory Questionnaire (SGRQ) (n = 4)
[16–18, 26]. Exacerbation severity was also assessed with questionnaires (n = 1)[19] and finally
breathlessness, cough and sputum were assessed using the Breath Cough and Sputum scale
(BCSS) (n = 1)[16].
Fig 1. PRISMA flow diagram.
https://doi.org/10.1371/journal.pone.0198920.g001
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Synthesis of results
Genetic variants and exacerbation frequency. Two coding GC SNPs rs4588 and rs7041
[25], 5 SNP’s and 7 haplotypes from MBL2 gene have been investigated for associations with
exacerbation frequency [14, 20, 22]. Only patients with C allele at the rs4588 polymorphism
(C/C: 83 patients; A/C: 45 patients; A/A: 7 patients (p = 0.0048)) [25], 3 MBL2 SNP’s and 1
haplotype were found significantly more prevalent in frequent exacerbators (p<0.01) [14, 20,
22]. HHIP, FAM13A and CHRNA3/5 SNPs were also assessed, however, only the rs13118928
SNP of the HHIP gene was found to be associated to previous and prospective exacerbations
(Incidence Rate Ratio = 0.877; p = 0.015 and IRR = 0.906;p = 0.024, respectively) [15]. SER-
PINA1 11478 G>A variant [23] and 25-hydroxyvitamin D receptor (VDR) polymorphisms
[24] were not associated with exacerbations frequency (α1-antitrypsine: p = 0.75; VDR poly-
morphisms: rs1544410: p = 0.43; rs731236: p = 0.64 rs2228570: p = 0.87) [23, 24]
Genetic variants and exacerbation severity. The A allele from the rs2282691 SNP in
CCL1 gene was found to be a risk allele for severity of exacerbation (OR 5.93; p = 0.023) [19].
Genetic variants and depression. Only the rs3794808 SNP from the 5 SLC6A4 gene poly-
morphisms (rs3794808; rs140701; rs140700; rs2020939; rs2020936) was considered signifi-
cantly associated with HADS depression score in patients with COPD (p = 0.022)[21].
Genetic variants and health-related quality of life. The impact of HO-1 and EPHX1
polymorphisms on treatments with N-acetylcysteine (NAC) was assessed [18, 26]. Better
health-related quality of life, assessed with the SGRQ, was found in patients without the L allele
(L-) of HO-1 gene, which is a (Gt)n polymorphism, than in those with the L allele (L+) relative
to the activity score of SGRQ (SGRQ activity score: Baseline: 46.2±14,5; 16 weeks: 46.3±11.0;
32 weeks: 46.7±12.2; 48 weeks: 47.4±15.5; p = 0.02)[18]. Additionally, patients having the slow
activity group of the EPHX1 genotype (based on exon 3 polymorphism) also revealed better
health-related quality of life than those having the fast activity group for the symptom score of
Table 1. Quality assessment scores for the selected studies based on the quality of genetic association studies (Q-Genie).
Studies Items
1 2 3 4 5 6 7 8 9 10 11 Score
Bleecker et al,2012 [16] 5 5 Na 5 4 5 6 5 6 5 5 51
Ishii et al, 2014 [25] 5 4 3 6 3 3 3 5 4 4 5 45
Ishii et al, 2011 [21] 6 4 5 4 2 5 2 3 4 4 5 44
Lin et al, 2011 [22] 5 6 3 5 2 3 3 5 2 4 4 42
Mandal et al, 2015 [14] 6 6 Na 3 2 6 1 4 3 5 6 42
Pillai et al, 2010 [15] 4 6 Na 5 5 4 5 6 5 4 6 50
Quint et al,2011 [23] 5 4 5 5 2 3 6 3 5 4 5 47
Quint et al, 2012 [24] 4 5 3 4 5 4 2 6 3 4 4 44
Takabatake et al, 2006 [19] 7 6 Na 6 5 5 3 6 6 5 6 55
Umeda et al, 2008 [17] 5 4 Na 4 4 5 2 4 4 3 4 39
Yang et al, 2003 [20] 6 6 4 5 5 5 3 5 5 5 6 55
Zhang et al,2015[26] 5 5 5 4 4 5 4 6 4 4 4 50
Zhang et al,2015 [18] 5 5 Na 4 4 4 5 6 4 4 5 46
1- rationale for study; 2- selection and definition of outcome of interest; 3- selection and comparability of comparison group (if applicable); 4- technical classification of
the exposure; 5- non-technical classification of the exposure; 6 other sources of bias; 7- sample size and power; 8- a priori planning of analysis; 9- statistical methods and
control for confounding; 10- testing of assumptions and inferences for genetic analysis; 11- appropriateness of inferences drawn from results. All items have a maximum
score of 7.
Na–not applicable
https://doi.org/10.1371/journal.pone.0198920.t001
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SGRQ (Slow activity group: baseline: 40.9±12.3; after NAC: 37.8±13.1; Fast activity group:
baseline: 41.7±13.5; after NAC 38.7±15.4; p<0.05) [26].
The impact of the Gly16Arg polymorphism of the ADRB2 gene on health-related quality of
life HRQOL was also assessed. Significant differences were observed in all domains and total
scores of SGRQ between both genetic groups (Arg/Arg and non- Arg/Arg), however only the
impact and total scores were significantly different in patients with the Arg/Arg genotype
(total score: -16.9 vs. -8.1, p = 0.005; impact score: -19.8 vs. -2.2 p<0.001)[17]. No significant
associations were found when investigating impact of the ADRB2 polymorphism on treatment
effect with budesonide/formoterol I(p = 0.909) and II(p = 0.648) on SGRQ[16].
Genetic variants and breathlessness, cough and sputum. No significant association was
found between the Gly16Arg possible genotypes of ADRB2 and the scores for the BCSS scale
(p>0.05)[16].
Discussion
This was the first systematic review to explore associations between genetics and PROs in
patients with COPD. The 13 studies included reported on 12 genetic variations positively asso-
ciated with 5 distinct PROs, i.e., exacerbation frequency and severity, depression, health related
quality of life and symptoms (breathlessness, cough and sputum).
Most studies (n = 7/13) assessed the association of specific genetic variants with exacerba-
tion frequency. This is an important remark since the frequency of exacerbations is strongly
associated with patients’ functional and physiological deterioration [27], reduced health
related quality of life [28] and substantial morbidity and mortality [29]. MBL2 was the gene
mostly associated with frequency of exacerbations (3/13) [14, 20, 22]. Several polymorphisms
of MBL2 gene play important roles in the innate immunity as it encodes for mannose-binding
lectine. The mannose-binding lectine is a pattern-recognition receptor that binds to the sugar
structure presented in various microorganisms[30]. Specific polymorphisms of the MBL2 gene
have been found responsible for causing a decreased production of MBL (MBL-deficient geno-
type), and this has been associated with an increased risk of exacerbations. In fact, high MBL
levels presented in serum have been associated with increased survival in COPD [14]. Thus,
MBL2 polymorphisms seem to be promising biomarkers to detect those with more susceptibil-
ity to exacerbations and good candidates for assessment with PRO-based approaches.
Polymorphisms in the GC and VDR genes causing deficits of vitamin D (associated with
several comorbidities, such as osteoporosis or skeletal muscle dysfunction, in patients with
COPD[31]), have also been connected to the frequency of exacerbations. Nevertheless, a
careful interpretation of the literature is needed since both significant and non-significant
associations between GC polymorphisms rs4588 and rs7041 or VDR (Bsm, Taql, Fokl) poly-
morphisms with frequency of exacerbations and lack of vitamin D have been reported [25, 32,
33]. Additionally, many non-genetic factors may also lead to vitamin D deficiency, namely the
absence of sun exposure, vitamin D retention on body fat or other social/cultural factors[31].
Therefore, future studies are yet needed to enhance our understanding of the relationship
between these polymorphisms, vitamin D deficiency and PRO in COPD.
Exacerbation severity has been significantly associated with a CCL1 allele for rs2282691 in
one study [19]. However, the authors’ definition of exacerbation severity can be arguable, as
they used death as endpoint. It is known that the severity of an exacerbation is not defined by
mortality but rather by symptoms and number and length of hospitalizations in the most
severe cases[34]. Since the authors have recorded patients’ main symptoms, it would be inter-
esting to assess if the reported A allele for rs2282691 was also associated with those and if the T
allele actually conferred protection to acute exacerbations of COPD, as suggested. Other
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option would be to explore the correlations between rs2282691 variant with specific instru-
ments, such as the Exacerbations of Chronic Pulmonary Disease Tool (EXACT-PRO)[35] to
assess the severity of exacerbations. This analysis would be essential to identify patients with
higher predisposition for more severe exacerbations which would allow them to be targeted
for more timely and directed monitoring and intervention.
Depression was found to be associated with the rs3794808 variant, affecting the SLC6A4
gene[21]. It is known that depression presents a strong linkage to nicotine dependence[36]
and SLC6A4 is strongly associated with the pathophysiology of tobacco use, namely at the level
of serotonin reuptake. Therefore, it would be expected that specific genetic variants of this
gene would play an important role on nicotine dependence and consequently depression in
ex/current smokers[37]. However, different SNPS of the SLC6A4 gene [38] and other genes
such as THSD4,CHRNA, CYP2A6[3] have also been associated with depression in COPD.
Thus, it would be valuable to confirm those associations populations patients with COPD with
different characteristics, such as smokers and non-smokers, to decide if future therapies should
take these genes into consideration. Currently, the most effective therapy to combat anxiety
and depression in patients with COPD is pulmonary rehabilitation (PR), which has been
shown to be significantly effective by reducing the levels of depression and anxiety symptoms
in patients with this disease [39]. However, PR is an expensive therapy and access to it is highly
limited [40]. Therefore, genetics may be used to signal priority patients to PR, and thus opti-
mize human and financial resources in managing COPD.
Four studies investigated ADRB2[16, 17], Ho-1[18] and EPHX1[26] association with health
related quality of life. The Gly16Arg polymorphism of ADRB2 has been indicated as a risk fac-
tor for COPD[41]. However, different results regarding its association with health-related
quality of life emerged from our systematic review. Umeda et al., showed that patients with
COPD and the Arg/Arg genotype presented better health related quality of life in treatments
with tiotropium[17] whereas no significant associations was found in the study of Bleecker
et al. for the same polymorphism and budesonide/formoterol treatment [16]. The most obvi-
ous explanation is the substance used in the treatments, since other studies using other LABAs
(long-acting b2-agonists) and LAMAs (long-acting muscarinic antagonists) have also pre-
sented no associations [42]. As for Ho-1 and EPHX1 polymorphisms, both genes presented sig-
nificant associations with SGRQ activity and symptoms sub-scores in patients with COPD that
were treated with N-acetylcysteine (NAC)[18, 26]. Pharmacogenetics studies are of significant
importance, since they investigate how genes affect a patient’s response to drugs. This knowl-
edge facilitates health-care by identifying patients that will respond differently to treatments.
Future studies assessing health related quality of life may also include these genetic variants
reported as being protective against COPD[43], since they may play an important role on
patients’ quality of life.
A final important aspect to emphasize is the ethnicity of the study populations. In this study
we intended to summarize the genetic variants associated with PROS in patients with COPD.
However, we observed that this systematic review included nine different ethnic groups from
which the majority (n = 7/13) were conducted in Asian countries. This may explain the diffi-
culty in obtaining similar results among different populations. For this reason, the ethnicity
was also indicated in Table 2.
PROs are increasingly being understood as excellent instruments to translate a range of out-
comes that spirometry cannot express, such as symptoms and patients’ perspective of treat-
ment[44]. However, there is a massive number of PROMs (patient-reported outcomes
measures) that were not found in this systematic review, and yet allow to assess other funda-
mental PROs such as mood, social and sexual life [6]. Also, it was shown that genetics play a
key role not only in the predisposition to the disease but also in common COPD-related
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comorbidities. Thus, further studies should be conducted to re-enforce the present knowledge
and assess the genetic influence on other dimensions of patients’ lives.
Limitations
This review has some limitations that need to be acknowledged. Firstly, the definition of PROs
(although published) has not been used as a primary outcome in some of the included studies.
Thus, few studies gave emphasis to it, giving priority to clinical outcomes which may have led
to significant loss of studies and information. However, to minimize this problem we per-
formed a meticulous choice of keywords to diminish the number of missed studies. Secondly,
the constant changes in the definition of exacerbation in the GOLD[1] may also result in loss
of studies over the years. We overcame this difficulty by enclosing studies which included par-
ticipants that had reported exacerbations independently of the definition used at the time.
Thirdly, studies used different methodologies to assess similar or different PROs and conse-
quently, prevented the realization of meta-analysis.
Conclusions
This was the first systematic review to explore associations between genetics and PROs in
COPD. Although a limited number of PROs have been successfully related to genetic varia-
tions, findings suggest that a significant association between specific genetic variants and the
frequency and severity of exacerbations, health-related quality of life and depressive symptoms
may exist. Thus, further research is needed to confirm these results and to assess the possibility
of association of other genetic variants with other PROs in patients with COPD, since this may
enhance our understanding and management of this disease.
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